Pages that link to "Q46590733"

The following pages link to The efficacy and safety of weekly vinorelbine in relapsed malignant pleural mesothelioma (Q46590733):

Displaying 46 items.

• BRCA1 is an essential mediator of vinorelbine-induced apoptosis in mesothelioma. (Q27851697) (← links)
• Immunological effects of the TGFβ-blocking antibody GC1008 in malignant pleural mesothelioma patients (Q28390399) (← links)
• Modern management of malignant pleural mesothelioma (Q29248127) (← links)
• Immunotherapy and radiation therapy for malignant pleural mesothelioma. (Q33645613) (← links)
• Novel systemic therapy against malignant pleural mesothelioma (Q33890499) (← links)
• Malignant pleural mesothelioma: an update on diagnosis and treatment options (Q34513958) (← links)
• Vinorelbine and gemcitabine as second- or third-line therapy for malignant pleural mesothelioma. (Q35129531) (← links)
• Chemotherapy and targeted therapies for unresectable malignant mesothelioma (Q35141369) (← links)
• Mesothelioma: a review (Q35839385) (← links)
• A phase Ia/Ib clinical trial of metronomic chemotherapy based on a mathematical model of oral vinorelbine in metastatic non-small cell lung cancer and malignant pleural mesothelioma: rationale and study protocol (Q35994241) (← links)
• Malignant pleural mesothelioma: update on treatment options with a focus on novel therapies. (Q36728254) (← links)
• Chemotherapy for malignant pleural mesothelioma: a review of current management and a look to the future (Q37090808) (← links)
• Malignant pleural mesothelioma: current and future perspectives (Q37217764) (← links)
• Systemic treatments for mesothelioma: standard and novel (Q37260408) (← links)
• Management of malignant pleural mesothelioma-part 2: therapeutic approaches : Consensus of the Austrian Mesothelioma Interest Group (AMIG). (Q37277434) (← links)
• A Phase II Study of Sorafenib in Malignant Mesothelioma: Results of Cancer and Leukemia Group B 30307 (Q37296603) (← links)
• Future developments in the management of malignant pleural mesothelioma (Q37449036) (← links)
• Inhibition of FGF/FGFR autocrine signaling in mesothelioma with the FGF ligand trap, FP-1039/GSK3052230. (Q37457703) (← links)
• Small bowel metastasis from pancreatic cancer in a long-term survival patient with synchronous advanced malignant pleural mesothelioma: A case report and literature review (Q37582256) (← links)
• An Unusually Large Pleural Mesothelioma with an Outstanding Clinical Response and Long Lasting Survival: A Case Report and Literature Review (Q37851123) (← links)
• Medical treatment of mesothelioma: anything new? (Q37866663) (← links)
• Systemic treatment of malignant pleural mesothelioma (Q37992694) (← links)
• Asbestos-related pleuropulmonary diseases: benign and malignant (Q38018217) (← links)
• Role of microRNAs in malignant mesothelioma. (Q38190418) (← links)
• Advances in treatment of mesothelioma. (Q38800916) (← links)
• Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial. (Q38909086) (← links)
• Second-line therapy in patients with malignant pleural mesothelioma. A French retrospective study (2005-2006) (Q42864235) (← links)
• Advances in systemic therapy for malignant mesothelioma: future perspectives (Q47912434) (← links)
• Medical treatment of malignant pleural mesothelioma relapses. (Q52672887) (← links)
• Chemotherapy treatment in malignant pleural mesothelioma: a difficult history. (Q52672893) (← links)
• Third-line chemotherapy with carboplatin, gemcitabine and liposomised doxorubicin for malignant pleural mesothelioma. (Q53641990) (← links)
• Gemcitabine and vinorelbine as second-line or beyond treatment in patients with malignant pleural mesothelioma pretreated with platinum plus pemetrexed chemotherapy. (Q54698040) (← links)
• Management of recurrent pleural mesothelioma: Successful rechallenge with nintedanib in combination with chemotherapy (Q57822522) (← links)
• Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up (Q59274199) (← links)
• Simultaneous presence of lung adenocarcinoma and malignant pleural mesothelioma: A case report (Q59796596) (← links)
• Characteristics and long-term outcomes of advanced pleural mesothelioma in Latin America (MeSO-CLICaP) (Q64235291) (← links)
• Efficacy and Safety of Avelumab Treatment in Patients With Advanced Unresectable Mesothelioma: Phase 1b Results From the JAVELIN Solid Tumor Trial (Q64285361) (← links)
• [Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma] (Q82061962) (← links)
• Malignant pleural mesothelioma (Q83412919) (← links)
• Malignant pleural mesothelioma (Q83466825) (← links)
• Chemotherapy for Malignant Pleural Mesothelioma (Q83789589) (← links)
• Tumour Treating Fields for mesothelioma: controversy versus opportunity (Q90808650) (← links)
• Ipilimumab and nivolumab in the treatment of recurrent malignant pleural mesothelioma (INITIATE): results of a prospective, single-arm, phase 2 trial (Q91123540) (← links)
• Relations between approved platinum drugs and non-coding RNAs in mesothelioma (Q91949964) (← links)
• Interplay of non-coding RNAs and approved antimetabolites such as gemcitabine and pemetrexed in mesothelioma (Q91949972) (← links)
• Product review: avelumab, an anti-PD-L1 antibody (Q93338919) (← links)